Dr. Matthews on the Efficacy of CPX-351 Vs Venetoclax/Azacitidine in AML

Andrew Matthews, MD, discusses the efficacy of CPX-351 vs venetoclax plus azacitidine in acute myeloid leukemia.

Andrew Matthews, MD, fellow, Division of Hematology and Oncology, Department of Medicine, Penn Medicine, discusses the efficacy of CPX-351 (daunorubicin and cytarabine; Vyxeos) vs venetoclax (Venclexta) plus azacitidine (Vidaza) in acute myeloid leukemia (AML).

The results of a real-world analysis demonstrated that the median overall survival (OS) was similar with CPX-351 and venetoclax/azacitidine in patients with AML at 13 months vs 12 months, respectively. Moreover, no clear advantage for one treatment over the other was observed in any of the subsets of patients evaluated, Matthews explains.

Additionally, a series of analyses were conducted as part of the study, such as a restriction analysis for patients who would have been eligible for the pivotal CPX-351 trial, multiple imputation to compensate for missing data, and multiple imputation and inverse probability of treatment waiting to balance covariates, Matthews continues. However, these analyses failed to demonstrate a statistically significant difference in OS between these 2 groups, Matthews concludes.